Featured Content

Winston Wong, PharmD
President, W-Squared Group

Examining the Rising Costs of Cancer Care

(WGGB-TV/ABC, Ch. 40 [Springfield, MA]) Nov 20, 2014 - It’s a grim reality and a dire decision facing thousands of cancer patients, even those with health insurance: the costs of treating cancer have skyrocketed and many sufferers can’t afford to stay alive.

Commentary: The fundamental points made here are accurate. The discrepancy between cost in the US vs. everywhere else goes...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Fat to Blame for Half a Million Cancers a Year, WHO Agency Says

(Reuters) Nov 25, 2014 - Some half a million cases of cancer a year are due to people being overweight or obese, and the problem is particularly acute in North America, the World Health Organization's cancer research agency said on Wednesday.
read article »

NICE Updated Guidance Recommends Imatinib for Digestive System Cancers

(NICE) Nov 26, 2014 - NICE has issued final guidance to the NHS recommending imatinib, also known as Glivec and made by Novartis, for up to 3 years for people who have had a gastro-intestinal stromal tumour (GIST) removed and who are at high risk of the cancer recurring.
read press release »

NICE Recommends More Options for Tackling Anaemia in People with Cancer

(NICE) Nov 26, 2014 - People with cancer who are having chemotherapy and who have anaemia will now have more treatments available through the NHS.
read press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Roche's Genentech Defends Supply Shift For Top Cancer Drugs (Reuters)

I find it disingenuous that Genentech totally ignores the significant increase in cost and direct transfer of funds...posted by: David Jaspan

Examining the Rising Costs of Cancer Care (WGGB-TV/ABC, Ch. 40 [Springfield, MA])

The fundamental points made here are accurate. The discrepancy between cost in the US vs. everywhere else goes...posted by: Winston Wong, PharmD

ASCO Takes Part in IOM Workshop on Molecularly Targeted Therapies for Cancer (ASCO in Action)

Hopefully this will help promote the molecular profiling space, and help payers gain confidence that these test...posted by: Winston Wong, PharmD

Cost to Develop a Drug More Than Doubles to $2.56 Billion (Bloomberg)

At the end of the day, transparency is the key to all of us understanding the cost of development, and what is...posted by: Winston Wong, PharmD

Payers Evaluate the Clinical Utility of Diagnostic Tests (AJMC.com)

The question that payers need answered with regards to covering molecular profiling test are really 2-fold. First,...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


NCCN has posted 1 new job.


Bayer Biopharmaceuticals, Inc. has posted 20 jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
IDRA +7.50%
SNTA +4.15%
IMMU +3.88%
CPXX -6.59%
CNDO -6.22%
MEIP -5.13%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: December 5, 2014
Company: Novartis / Incyte Corp.
Product: Jakafi® (ruxolitinib)

Date: January 3, 2015
Company: AstraZeneca PLC
Product: Olaparib

Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

See All OBR Radar items»